2024 perioperative cardiovascular guideline: practical extraction for OMFS oncology and reconstruction

Source: Thompson et al. Circulation. 2024;150:e351–e442. DOI: https://doi.org/10.1161/CIR.0000000000001285.

References below use PDF viewer page numbers, followed by printed journal pages where helpful. PDF page 1 = e351. This is an extraction of the specified 2024 document, not a comprehensive review of subsequent perioperative guidance.

Recommendation strength: Class 1 = recommended; 2a = reasonable/useful; 2b = may be considered; Class 3 = no benefit or harm. A 2b recommendation is an option, not a universal requirement. “OMFS application” labels clinical interpretation rather than a recommendation specifically studied in free-flap surgery.

1. Classify the operation and its urgency correctly

The guideline combines patient and procedural factors: low cardiovascular risk means predicted major adverse cardiovascular events (MACE) <1%; elevated risk means ≥1%. Its broad specialty categories are guides, not substitutes for a procedure-specific assessment. Minor dental procedures appear among very-low-risk examples. Do not apply that category automatically to a composite oral cancer resection with neck dissection and free-flap reconstruction. [§1.5, PDF p7/e357]

Use a validated calculator such as RCRI or ACS NSQIP/MICA, together with functional capacity and risk modifiers. The guideline does not endorse one calculator as universally superior. RCRI’s procedure item covers intraperitoneal, intrathoracic, or vascular surgery: it does not directly describe the complexity of a long head-and-neck reconstruction. [§3.1, pp10–12]

OMFS application: record the planned procedure, anticipated duration/blood loss, comorbidities, and a calculated risk. Do not let the label “oral surgery” or a low RCRI alone settle the assessment.

The guideline defines time-sensitive surgery as surgery that can be delayed up to 3 months for evaluation/management without adverse effects on outcome. This is a classification, not permission to delay a particular cancer for 3 months. The oncology team must specify the actual acceptable delay. [Table 2, p7]

2. Identify conditions that change the plan before ordering routine tests

Figure 1 calls for management of acute coronary syndrome, unstable arrhythmias, or decompensated heart failure, with multidisciplinary consideration of deferral or alternatives. Emergency surgery follows a different path and proceeds with appropriate perioperative management. [Figure 1, p21/e371]

Other risk modifiers requiring targeted evaluation include severe valve disease, severe pulmonary hypertension, prior PCI/CABG, recent stroke, implanted cardiac devices, congenital heart disease, and frailty. A reassuring risk score does not remove these issues. [Figure 1, p21]

• Severe aortic stenosis: evaluate the need for valve intervention before elective surgery (Class 1). Suspected moderate/severe stenosis before elevated-risk surgery warrants echocardiography (Class 1). The permission to proceed in selected asymptomatic patients applies to low-risk surgery and should not be transferred automatically to major reconstruction. [§6.4.1, pp30–32]
• Heart failure: risk exists even with preserved EF; worsening symptoms matter. Continue appropriate guideline-directed therapy in compensated HF, except SGLT2 inhibitors, unless contraindicated (2a). Consider postponing elective surgery in clinically decompensated/unstable advanced HF. [§6.3, pp25–26]
• Severe pulmonary hypertension: specialist-center consultation and an appropriate monitoring/postoperative care plan are reasonable; continue established targeted pulmonary arterial hypertension therapy (Class 1). [§6.3.2, pp26–28]
• Prior stroke/TIA: delaying elective surgery ≥3 months after the most recent event is reasonable (2a). For time-sensitive cancer surgery, discuss the competing oncologic and cerebrovascular risks explicitly. [§6.7, p39]

3. Use testing selectively to avoid unnecessary oncologic delay

Assessment	Guideline recommendation	OMFS application
Functional capacity	Structured assessment such as DASI is reasonable before elevated-risk surgery (2a). Poor capacity is <4 METs or DASI ≤34. [pp12–13,17]	Record an objective functional history. Poor function from frailty or illness is still relevant even without angina.
Frailty	Validated assessment is useful in older adults and younger patients with perceived frailty undergoing elevated-risk surgery (2a). [pp13–14]	Include frailty alongside nutrition, weight loss, and ability to recover from reconstruction.
ECG	Reasonable with known cardiovascular disease or symptoms before elevated-risk surgery; new abnormalities merit evaluation (2a). May be considered as a baseline in asymptomatic elevated-risk patients without known disease (2b). [p15]	Provides a baseline if postoperative tachycardia, ischemia, or arrhythmia occurs. QT prolongation can affect drug choices.
Echocardiography	Recommended for new dyspnea, HF signs, or suspected new/worsening ventricular dysfunction (1). Routine LV assessment in stable asymptomatic patients offers no benefit (3). [p16]	A long operation alone does not mandate an echo; a new murmur or unexplained dyspnea may.
BNP/NT-proBNP	Reasonable with known CVD, age ≥65, or age ≥45 with suggestive symptoms, when undergoing elevated-risk surgery (2a). [p14]	Can refine risk and the need for additional evaluation/monitoring.
Preoperative troponin	May be reasonable in the same groups (2b). [p14]	A baseline helps interpret a postoperative rise.
Stress testing	May be considered only in selected patients with elevated procedural/calculated risk and poor/unknown capacity (2b); routine testing with low risk or adequate stable capacity is not recommended (3). [p17]	Ask in advance what a positive test would change. Poor capacity does not automatically require stress imaging.

Figure 1 flags BNP >92 ng/L, NT-proBNP ≥300 ng/L, or troponin above the assay’s 99th-percentile upper reference limit. These are risk-assessment thresholds, not automatic cancellation criteria; the text acknowledges uncertainty about optimal biomarker thresholds. [pp14,21]

Routine invasive coronary angiography is not recommended. Routine coronary revascularization for stable non-left-main CAD solely to reduce surgical events is not recommended. ACS and significant left-main stenosis (≥50%) require a different evaluation. [§4.6 and §6.1.1, pp20,22]

4. Recent coronary stents: establish the dates before scheduling

The following timing recommendations apply particularly when ≥1 antiplatelet agent must be interrupted:

Coronary intervention	Timing in the 2024 guideline	Strength
Balloon angioplasty without stent	Delay elective surgery at least 14 days	1
Drug-eluting stent (DES) placed for ACS	Ideally delay elective surgery ≥12 months	1
DES placed for chronic coronary disease	Delay elective surgery ≥6 months is reasonable	2a
DES with time-sensitive surgery	Surgery may be considered ≥3 months if harm from delay outweighs cardiac risk	2b
Bare-metal stent or DES placed ≤30 days ago	Elective surgery requiring antiplatelet interruption is potentially harmful	3: Harm

[§7.5, PDF pp43–45/e393–e395; Figure 5]

After prior PCI, continue aspirin 75–100 mg if possible (Class 1). If time-sensitive surgery is needed within 30 days of a bare-metal stent or <3 months of a DES, continue dual antiplatelet therapy unless bleeding risk outweighs protection from stent thrombosis (Class 1). Selected very-high-risk patients may be considered for specialist intravenous antiplatelet bridging (2b). This differs from heparin bridging for an oral anticoagulant. [p43]

OMFS application: explicitly discuss the consequences of neck hematoma, airway compromise, pedicle compression, donor-site bleeding, and possible re-exploration alongside stent thrombosis and cancer progression. This calls for a joint OMFS–anesthesia–cardiology decision, rather than a standard instruction to stop all blood-thinning drugs.

If interruption is agreed, Table 12 gives minimum intervals for platelet function recovery: aspirin 4 days; clopidogrel 5–7 days; prasugrel 7–10 days; ticagrelor 3–5 days. These are not instructions to interrupt therapy regardless of indication. [p43]

Without prior PCI, continuing aspirin for chronic coronary disease may be reasonable when cardiac risk outweighs bleeding risk (2b). Routine initiation of aspirin solely for elective noncarotid surgery offers no benefit (3). This does not answer whether aspirin should be prescribed for a microvascular flap. [p43]

5. Chronic anticoagulation: plan interruption and restart separately

Time-based interruption should account for drug, renal function, bleeding risk, and thrombotic indication (Class 1). Routine therapeutic heparin bridging is harmful in most patients because it increases bleeding. Selected patients at high thrombotic risk interrupting warfarin may benefit from bridging (2a). Restart anticoagulation after hemostasis is achieved (2a). [§7.6, pp46–49]

Illustrative high-bleeding-risk schedules from Table 13: day 0 is surgery. These require individualization and are not a substitute for the prescriber’s plan.

Drug/renal function	Days on which drug is withheld before surgery, plus day 0	Table’s postoperative schedule, only if hemostasis permits
Apixaban, edoxaban, rivaroxaban; without the table’s severe renal impairment category	−2, −1, 0	Withhold +1/+2; resume +3
Same drugs, CrCl <30 mL/min	−3, −2, −1, 0	Withhold +1/+2; resume +3
Dabigatran, CrCl ≥50 mL/min	−2, −1, 0	Withhold +1/+2; resume +3
Dabigatran, CrCl <50 mL/min	−4, −3, −2, −1, 0	Withhold +1/+2; resume +3
Warfarin, low/moderate thrombotic risk	−5 through 0	Table shows restart +1; confirm hemostasis and appropriate INR plan

[p47/e397; table visually inspected]

High thrombotic risk includes mechanical mitral valves, recent VTE, recent cardioembolic stroke, certain very-high-risk AF profiles, recent LV thrombus, and severe thrombophilia. Active cancer increases thrombotic risk but does not automatically make every patient a bridging candidate. [Table 14, p48]

Correction check: the official November 2024 correction removed mechanical mitral valves from the moderate-risk row. The downloaded PDF already reflects this: mechanical mitral valve appears in the high-risk row. Official correction

OMFS application: distinguish (1) chronic therapeutic anticoagulation, (2) perioperative VTE prophylaxis, and (3) any flap-directed antithrombotic regimen. “Do not routinely bridge” does not mean omit appropriate VTE prophylaxis. The guideline does not establish a free-flap antithrombotic protocol.

6. Medication decisions worth putting on the preoperative checklist

Medication	Recommendation	Source
Established beta blocker	Continue as clinically appropriate (1). If newly indicated, start sufficiently early, optimally >7 days, for titration (2b). Do not initiate on surgery day without an immediate indication (3: Harm).	p49
Statin	Continue (1). Start when otherwise indicated for ASCVD/long-term prevention, with intention of ongoing use (1).	p40
ACE inhibitor/ARB or other RAAS inhibitor used for hypertension	In selected patients with controlled BP having elevated-risk surgery, omission 24 hours beforehand may reduce intraoperative hypotension (2b).	p41
RAAS inhibitor used for HFrEF	Perioperative continuation is reasonable (2a), considering clinical circumstances.	p41
SGLT2 inhibitor	Stop canagliflozin, dapagliflozin, empagliflozin ≥3 days; ertugliflozin ≥4 days before scheduled surgery (1). Applies to diabetes and HF use.	pp25,50

OMFS application: anticipate postoperative inability to swallow. Before surgery, document how essential chronic medicines will be administered and when held drugs can be restarted. Do not assume every formulation can be crushed or delivered through a feeding tube.

7. Hemodynamics, anemia, and the long reconstruction

Maintain intraoperative MAP ≥60–65 mm Hg or SBP ≥90 mm Hg (Class 1). Treat postoperative hypotension below these thresholds (Class 1). These are cardiovascular safety thresholds, not a validated optimal flap-perfusion target; individual patients may need a higher target. [§6.2, p23]

In patients having elective elevated-risk surgery with cardiovascular risk factors and a recent history of poorly controlled BP (SBP ≥180 or DBP ≥110 before surgery day), deferral may be considered (2b). A single isolated reading is not equivalent to that full recommendation. Restart antihypertensives as soon as clinically reasonable. [pp23–24]

OMFS application: agree on BP, volume, and bleeding management with anesthesia. The guideline does not settle a free-flap vasopressor-versus-fluid strategy. Avoid interpreting flap-perfusion concerns as a reason to tolerate sustained systemic hypotension or to disregard HF-related fluid intolerance.

Treat iron-deficiency anemia preoperatively with oral or IV iron when feasible (2a). Tranexamic acid is reasonable when blood loss is expected (2a), but this general recommendation does not by itself establish safety, dose, or net benefit for every microvascular cancer reconstruction. [§8.4, pp55–56]

The text discusses restrictive transfusion practices, including an 8 g/dL threshold for patients with cardiovascular disease, citing external transfusion guidance. It does not establish a mandatory hemoglobin ≥10 g/dL for free-flap survival. Active ischemia, ongoing bleeding, and physiology require individual assessment; this 2024 text is not a complete contemporary transfusion protocol. [p55]

Normothermia is reasonable (2a). For general anesthesia, volatile agents and TIVA have no apparent difference in cardiovascular events (2a). Unexplained hemodynamic instability may warrant emergency focused cardiac ultrasound or TEE where expertise is available (2a); feasibility of TEE must be considered in oral/pharyngeal surgery. [pp51,53–54]

8. Monitor for silent postoperative myocardial injury

In patients with known CVD, symptoms of CVD, or age ≥65 plus cardiovascular risk factors, undergoing elevated-risk surgery, troponin measurement at 24 and 48 hours may be reasonable (2b). This is selective surveillance, not universal screening. [§9.1, p56/e406]

Myocardial injury after noncardiac surgery (MINS) may be clinically silent. A troponin elevation needs interpretation: evaluate serial change, ECG, hemodynamics, and possible ischemic or nonischemic causes. Sepsis, pulmonary embolism, and other nonischemic causes must not simply be labeled MINS. [pp56–59]

OMFS application: prolonged anesthesia, analgesia, tracheostomy, and impaired speech can hinder recognition of symptoms. Specify troponin surveillance and the response to an abnormal result before surgery in selected elevated-risk patients. Review bleeding/anemia, hypoxia, hypotension, tachycardia, and cardiac causes promptly.

MINS warrants follow-up to optimize cardiovascular risk (2a). Antithrombotic treatment may be considered (2b), but an isolated troponin rise does not automatically justify full-dose anticoagulation after a fresh neck dissection or free flap. Postoperative STEMI/NSTEMI needs urgent multidisciplinary assessment balancing coronary treatment with surgical bleeding. [pp56–59]

9. Postoperative AF and implanted devices

For rapid AF, treat contributing triggers such as sepsis, anemia, and pain (2a), alongside appropriate rate/rhythm management. New postoperative AF requires assessment of anticoagulation benefit versus bleeding (2a), and outpatient thromboembolic risk assessment and rhythm surveillance (1). Resolution before discharge does not remove the follow-up requirement. [§6.5, pp35–36]

Head-and-neck surgery is above the umbilicus and commonly uses electrosurgery. For pacemakers/ICDs, establish the device type, pacing dependence, and anticipated interference before surgery. Pacemaker-dependent patients may need asynchronous pacing; a pacemaker-dependent patient with a transvenous ICD requires reprogramming, not reliance on an ICD magnet to supply asynchronous pacing. Restore appropriate device function before discharge from monitoring/home. [§6.6, pp36–39]

OSA screening with a validated questionnaire is reasonable (2a). In OMFS, interpret screening alongside tumor-related airway anatomy and postoperative airway/analgesic needs; the guideline does not provide an airway reconstruction protocol. [§6.8, pp39–40]

Suggested one-page case-conference checklist

This is an OMFS workflow derived from the guideline, not a validated guideline checklist.

• What is the maximum oncologically acceptable delay?
• Any ACS, decompensated HF, unstable arrhythmia, severe valve disease, severe PH, or recent stroke?
• Calculated cardiovascular risk, DASI/functional capacity, and frailty documented?
• Which tests would change management? ECG/echo/biomarkers selected accordingly?
• Any coronary stent: date, type, indication, and written antiplatelet plan?
• Any anticoagulant: indication, renal function, last dose, bridging decision, restart criteria?
• Chronic cardiovascular drugs and postoperative administration route planned?
• Anemia assessed and treated where feasible; blood conservation plan agreed?
• BP/volume targets, device precautions, and postoperative care location agreed?
• Troponin surveillance needed at 24/48 hours, and who responds to a rise?
• Who follows new AF or MINS after discharge?

The guideline supplies a cardiovascular framework. It does not establish flap-specific aspirin/heparin dosing, a preferred free-flap vasopressor, flap-specific MAP or hemoglobin targets, or oncologically safe delay intervals for individual tumors.